ヒト女性乳癌における男性ホルモン、アンドロゲンの局所産生と作用機序の解明

上述研究结果表明，在TNBC标本中，AR表达与较低的增殖水平相关，并且在同样表达雄激素合成途径酶的样本中，这种相关性更强。这一结果实际上与我们最初的假设相反，基于其他研究报告，雄激素受体水平非常高而缺乏雌激素受体的组预后更差，这与该领域研究的主导组的结果相反。这一发现的新颖性得到了国际科学会议ENDO2012总统海报竞赛的认可，并被邀请在2012年金泽举行的第15届>激素类固醇和激素与癌症国际大会上发表演讲，随后发表在《癌症科学》杂志上。由于这一最初矛盾的发现，我们一直在寻找可能的解释，以调和总体趋势，即病理分析显示雄激素受体是潜在的增殖抑制因子，而细胞系和分子分析表明雄激素受体是潜在的致癌基因。目前正在考虑发表在《乳腺癌研究与治疗》杂志上的最新数据表明，在三阴性乳腺癌中，可能至少有两种不同类型的AR表达TNBC。结合其他研究小组最近的两份报告，这可能为TNBC患者选择AR靶向药物治疗提供重要信息。除此之外，最近的论文表明，ERβ在乳腺癌中的作用，结合雄激素受体和ERβ受体配体之间已知的重叠，导致扩大了研究这些因素在TNBC中的项目。

Results of the research above revealed that AR expression in TNBC specimens correlated with lower levels of proliferation and this association was stronger in samples that also expressed enzymes for androgen synthetic pathways. This result was actually contrary to our original hypothesis, based on the research reports from others that groups characterized by very high levels of androgen receptor in the absence of estrogen receptor had a worse prognosis, and is contrary to the results of the dominate group in this area of research. The novelty of this finding was recognized by the research being awarded a prize in the presidential poster competition at the international scientific meeting ENDO2012, lead to an invitation to speak at the 15^<th> International congress on hormonal steroid and hormones & cancer in Kanazawa in 2012 and was subsequently published in the journal cancer science. Since this original contradictory finding we have been searching through possible explanations that reconcile an overall trend showing the pathological analysis reveals the androgen receptor to be a potential suppressor of proliferation, yet cell line and molecular analysis suggesting the androgen receptor as a potential oncogene. Recent data, currently under consideration for publication in the journal breast cancer research and treatment suggests that in triple negative breast cancer there may be at least two distinct types of AR expressing TNBC. In tandem with two recent reports from other groups this may provide important information in patient selection when choosing AR targeting agents as a therapy in TNBC. In addition to this, recent papers suggesting a role of ERβ in breast cancer, combined with the known overlap between androgen receptor and ERβ receptor ligands has led to an expansion of the project to investigate these factors in TNBC.